Drug Trial Radar · NCT01636076
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
Nov 2012
Primary completion
Sep 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD
Conditions
- COPD
Interventions
QMF149Drug
delivered via Concept1 device
SalmeterolDrug
delivered via Accuhaler®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85Time frame: 12 weeks
Locations
115 sites in 18 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Concord, New South Wales, Australia
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
New Lambton Heights, New South Wales, Australia
Novartis Investigative Site
Redcliffe, Queensland, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Daw Park, South Australia, Australia
Novartis Investigative Site
Woodville South, South Australia, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Fitzroy, Victoria, Australia
Novartis Investigative Site
Franston, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Halen, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Veliko Tarnovo, Bulgaria
Novartis Investigative Site
Rousse, Bulgaria, Bulgaria
Novartis Investigative Site
Varna, Bulgaria, Bulgaria
Novartis Investigative Site
Copenhagen NV, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Hellerup, Denmark, Denmark
Novartis Investigative Site
Hvidovre, Denmark, Denmark
Novartis Investigative Site
Pori, Finland
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Turku, Finland, Finland
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Donaustauf, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Großhansdorf, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Rüdersdorf, Germany
Novartis Investigative Site
Witten, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Wiesbaden, Germany, Germany
Novartis Investigative Site
Athens, Greece
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.